PFE  Pfizer Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.305 (+0.886%)

Growth Price

Overvalued by 17.06%

Stability Price

Overvalued by 65.44%

Company Metrics

  • 24.112 P/E
  • 4.318 P/S
  • 3.152 P/B
  • 1.441 EPS
  • 12.30% Cash ROIC
  • 1.67 Cash Ratio
  • 1.12 / 3.3% Dividend
  • 25.79M Avg. Vol.
  • 213.95B Market Cap.

Company Description

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segment's provides Lipitor for elevated LDL-cholesterol levels in the blood; Enbrel for rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diab...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Pfizer Inc. Gets FDA Green Signal For The First Drug To Treat A Rare Lung ...
Bidness ETC - 17 hours ago
Pfizer Inc. (NYSE:PFE) on Thursday won the US Food and Drug Administration's (FDA) approval for Rapamune, the first drug approved for the treatment of a rare, degenerative lung disorder called lymphangioleiomyomatosis (LAM).
Pfizer (PFE) Stock Gaining on Rare Lung Disorder Treatment Approval -
Pfizer Gets OK On Drug For Rare Lung Disorder - Benzinga
Pfizer Moves Up In Market Cap Rank, Passing Procter & Gamble
Forbes - 7 hours ago
Market capitalization is an important data point for investors to keep an eye on, for various reasons. The most basic reason is that it gives a true comparison of the value attributed by the stock market to a given company's stock. Many beginning ...
Active Morning Movers: Pfizer Inc. (NYSE:PFE), Biocept, Inc. (NASDAQ:BIOC ...
wsnewspublishers - 13 hours ago
On Friday, in the course of current trade, Shares of Pfizer Inc. (NYSE:PFE), gained 0.15%, and is now trading at $34.49. Pfizer, declared initial results of its global survey of more than 3,600 adults with rheumatoid arthritis (RA) in 13 countries.
Most Active Drug Manufacturing: Pfizer Inc. (NYSE:PFE), Merck & Co. Inc. (NYSE ... - StreetWise Report
Glaxo Bulls Awaken With Calls as Pfizer Merger Chatter Escalates
Bloomberg - 21 hours ago
“A lot of this is down to rumors about a merger with Pfizer,” said Kari Olsen, a sales trader at Tavira Monaco Sam. “There is also talk that if the CEO does go, the stock can spike up some 10 percent on the back of people thinking that the company can ...
Is Shire A Takeover Target For Pfizer?
Seeking Alpha - May 27, 2015
Shire's already excellent product portfolio, its strong rare disease drug pipeline, and its proven ability to leverage M&A to create value makes the company an attractive investment in general, but its strong strategic fit into Pfizer's rare disease ...
Active Stocks in the Spotlight: Pfizer Inc. (NYSE:PFE), National Bank of ...
wsnewspublishers - May 28, 2015
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); ...
Investors Selling These Stocks On Strength: QUALCOMM, Inc. (NASDAQ:QCOM ... - Wall Street Observer
Pfizer's Buy Rating Reiterated at Jefferies Group (PFE) - WKRB News
2 Under-the-Radar Updates Pfizer Inc.'s Shareholders Need to Know About
Motley Fool - May 6, 2015
Pfizer (NYSE: PFE ) is a mind-bogglingly large pharmaceutical company. As such, its quarterly updates tend to focus almost exclusively on high-profile products like the pneumococcal conjugate vaccine Prevnar 13, or clinical candidates such as its ...
Better Dividend Stock: Pfizer, Inc. or GlaxoSmithKline plc?
Motley Fool - May 13, 2015
Dividend stocks are undoubtedly powerful investing vehicles that can greatly amplify gains over a long period of time. That said, it's no easy feat to pick the right dividend stocks for your portfolio.
Stocks Lure Investment- Pfizer Inc. (NYSE:PFE), ATA, Inc. (NASDAQ:ATAI ...
StreetWise Report - 13 hours ago
The French biotech company Cellectis (CLLS) is in talks regarding its possible sale by means of Pfizer Inc. (NYSE:PFE) [Trend Analysis] of the US thought to be amid the buyers, according to the Financial Times quoting people familiar with matter.
Pfizer Inc.-GlaxoSmithKline Merger Talk: Deutsche Bank Speculates “PfizerKline”
Bidness ETC - May 21, 2015
Rumors have already been crossing wires that Pfizer Inc. (NYSE:PFE) might be interested in a takeover of its UK-based rival GlaxoSmithKline plc (ADR) (NYSE:GSK).
Deutsche Bank claims Pfizer Inc. (NYSE:PFE) Would Benefit From Glaxo Buyout - USMarketsDaily (blog)
How a "PfizerKline" would impact the Triangle - Triangle Business Journal